… CASTOR study in relapsed or refractory multiple myeloma, daratumumab, bortezomib, and
dexamethasone (… D-Vd versus Vd in CASTOR after a median follow-up of 40.0 months (nearly …

… III CASTOR study (median follow-up, 7.4 months), daratumumab plus bortezomib and
dexamethasone (… bortezomib and dexamethasone (Vd) alone in patients with RRMM. After longer …

… At data cut-off, the median follow-up for patients included in this … (25.5%) patients were
previously treated with other innovative … The median PFS was not reached (NR) in the CASTOR …

… In the global phase 3 CASTOR study, at a median follow-up of 50.2 months, daratumumab
in combination with Vd (D-Vd) resulted in a 69% reduction in the risk of disease progression …

… With the initial analysis of POLLUX at a median follow-up of 13.5 months, daratumumab
in … with daratumumab plus bortezomib and dexamethasone in the phase III CASTOR trial, …

… lenalidomide-based therapies in multiple myeloma (MM), … dexamethasone and daratumumab
(KdD) and daratumumab … More mature CASTOR data (median follow-up time 47.0 months) …

… median follow-up of 27.0 months (19.732.5), 19 (57.6%) patients … Treated Multiple Myeloma:
Three-year Follow-up of CASTOR… en los resultados del ensayo CASTOR junto con los datos …

… or the last known follow-up visit for censored patients, and ≥ … 47/57 cases were previously
treated with a bortezomib-based … in the pivotal CASTOR trial (16 months vs 7.8 months) [10]. …

… daratumumab, bortezomib, and dexamethasone in previously treated multiple myeloma (CASTOR…
in relapsed/refractory multiple myeloma: extended follow-up of POLLUX, a randomized…

… Median follow-up was calculated by the reverse Kaplan–Meier … the Castor trial comparing
daratumumab plus bortezomib plus dexamethasone versus bortezomib plus dexamethasone, …